|
|
535 Madison Avenue
New York, NY 10022 USA
phone:212-396-2766
fax:
|
|
| Symbol |
private |
| Founded |
0 |
| Employees |
|
|
|
|
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Treatment for diseases of the central nervous system |
|
| Management |
|
| |
|
|
| |
|
| Keywords |
| CNS, biopharmaceuticals, MS, AD, MCI |
|
|
|
| Description |
|
Memen Pharmaceuticals is a biopharmaceutical company focused on discovering and developing products to treat diseases of the central nervous system (CNS). The Company is initially developing a symptomatic treatment for memory disorders in patients with CNS conditions such as Multiple Sclerosis (MS), Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), and Traumatic Brain Injury (TBI), among others. Memen currently has two product candidates in development, C105 and SN522. Results of a recent Phase II trial indicate that C105 is capable of exceptional efficacy in improving memory function in patients with memory impairment secondary to MS. This earlier-stage biotechnology company recently met with the FDA to affirm key research goals and methodology, and the Division agreed that the development of an effective treatment for memory impairment in MS patients would be a worthwhile endeavor, as such problems are associated with considerable functional impairment and there is no current effective treatment for them. |
|
| Technology / Differentiation |
| Memen Pharmaceuticals LLC is initially developing a symptomatic treatment for memory disorders in patients with CNS
disorders such as Multiple Sclerosis (?MS?), Alzheimer?s disease (?AD?), Mild Cognitive Impairment (?MCI?) and Traumatic Brain Injury (?TBI?) among others. Memen currently has two product candidates in
development, C105 and SN522.
C105, the Company?s lead product candidate is l-amphetamine, which recently completed a Phase II trial for the treatment of cognitive function in MS patients with clinically significant cognitive impairment. The trial
was a 6-week randomized, double-blind and placebo-controlled study of 151 subjects from 33 sites in the
U.S. Patients were administered a standardized cognitive assessment test, the Minimal Assessment of
Cognitive Function in Multiple Sclerosis (?MACFIMS?) test, at baseline and were then titrated to 30mg of
C105 over the initial 2 weeks. After being on a 30 mg dose for 2 weeks, patients were reassessed with
MACFIMS, and a subset of measures was administered following a 2 week washout period. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members